X9 has won FDA Breakthrough Device Designation for its investigational power-assisted ultrasound needle-insertion system, the privately held, DaVita-backed startup announced 26 October 2026, the same day it disclosed completing ACCESS-2, a second clinical study of the device in hemodialysis patients. The designation covers a system that builds on an ultrasound-only version X9 already markets under a separate FDA clearance, adding guided needle insertion for the arteriovenous fistula punctures dialysis patients undergo several times a week.
X9's second nod, in four figures
Figures from X9's 26 October 2026 GlobeNewswire announcement and prior trade-press funding coverage.
How a Wallingford vascular-access startup got its second FDA nod
X9 did not start as an independent company chasing a dialysis problem on its own; it launched in 2022 out of ExploraMed, the Mountain View, California incubator that has spun out a string of device startups under founder Josh Makower. DaVita, one of the two largest U.S. dialysis providers, backed X9's seed round through its venture arm and later led a Series B, giving the startup a direct line to the clinics where its device would eventually need to work. That structure — an incubator-built startup with its primary customer already an investor — is why X9's FDA progress has moved on two tracks at once: an ultrasound-only system already cleared for sale, and a power-assisted needle-insertion version still working through investigational studies toward its own clearance.
X9's two decades compressed into four years
- 2022
X9 launches from ExploraMed
Founded in Wallingford, Connecticut, out of the ExploraMed incubator, with DaVita's venture arm as primary seed investor.
- Reported
$8.6 million raised
Hartford Business Journal reported an X9 funding round of $8.6 million to develop its dialysis needle-insertion technology.
- November 2025
First-in-human feasibility study
X9 announces successful completion of its first-in-human feasibility study of the power-assisted needle-insertion device.
- Prior to Oct 2026
Ultrasound-only system cleared
FDA clears X9's ultrasound-only system (510(k) K251673) for vascular access imaging in hemodialysis.
- 26 October 2026
Breakthrough Designation and ACCESS-2
FDA grants Breakthrough Device Designation to the power-assisted system; X9 announces completion of the 10-patient ACCESS-2 study the same day.
- Ahead
Pursuing marketing authorization
X9 has not disclosed a filing date for the power-assisted system's own FDA clearance or authorization.
What the designation adds to an already-cleared system
A Breakthrough Device Designation does not put a new product on the market; it moves X9's review to the front of FDA's queue and opens more frequent agency engagement while the power-assisted system's own clearance is still pending. X9's own release is explicit that the designation is not FDA clearance or approval of the device and does not guarantee future marketing authorization — a distinction that matters here because X9's ultrasound-only imaging system is already cleared and in use, while the power-assisted needle-insertion add-on is the piece still investigational.
“The X9 Ultrasound System is designed to address barriers in vascular access, simplifying workflows and reducing reliance on specialized operator training.” Eb Bright, Chief Executive Officer, X9 — from the company's November 2025 first-in-human announcement
Ultrasound guidance for a needle, not just an image
Point-of-care ultrasound has been used informally in dialysis units for years to find a fistula that a blind, by-feel cannulation attempt would otherwise miss, but most of that use pairs a general-purpose ultrasound probe with a conventional needle and a clinician's own hand-eye coordination. X9's power-assisted system adds mechanical, imaging-guided needle insertion on top of its already-cleared ultrasound imaging, using standard disposable dialysis needles so it integrates into a clinic's existing supply chain rather than requiring a proprietary consumable. Published trial literature on ultrasound-guided cannulation generally reports fewer additional needle passes and skin punctures than blind technique, at the cost of somewhat longer time to cannulate — the tradeoff X9's clinical program is built to characterize for its own specific device.
Three gaps X9 is built to close
Guidance, not just a picture
Pairing ultrasound imaging with power-assisted needle insertion targets the gap between seeing a vascular access site and actually hitting it, rather than leaving the insertion itself to an unassisted hand.
Built for difficult access
Miscannulation and first-attempt complication rates reported in dialysis nursing literature run meaningfully above zero even with experienced staff; a guided system is aimed squarely at that variability rather than at replacing routine, uncomplicated punctures.
A customer that is also an investor
DaVita's venture arm backing X9 from seed through Series B gives the startup an unusually direct channel into the clinics where its device must ultimately perform, a structural advantage over a vascular-access startup building without a dialysis-provider investor.
A needle market measured in hundreds of millions
The category X9's disposable needles sit inside is a narrow slice of a much larger vascular-access business. QYResearch, via Valuates, sizes the global AV fistula needle market at roughly $193.9 million in 2024, growing to about $241.1 million by 2030. Zoom out further and Fortune Business Insights puts the entire vascular access procedures market — catheters, ports and grafts included, not just dialysis fistula needles — at $96.89 billion in 2025, growing at a 5.38% compound annual rate. X9's device does not compete for that larger figure directly; it is a guidance system layered onto the much smaller needle category, sold alongside the hardware that makes the guidance possible.
A narrow needle market inside a $97 billion category
$193.9M → $241.1M
Global AV fistula needle market, 2024 actual to 2030 forecast, per QYResearch; the much broader vascular access procedures category is shown for scale.
Sources: Valuates Reports, Global Arteriovenous (AV) Fistula Needle market report (QYResearch) · Fortune Business Insights, Vascular Access Procedures Market
Regulatory News outlook
X9 is not selling into the $97 billion vascular-access category as a whole; its disposable needles and guidance hardware compete inside the much smaller AV fistula needle segment, where QYResearch's forecast implies the entire addressable needle category reaches roughly a quarter-billion dollars by 2030, before accounting for whatever premium a guided, power-assisted system can command over an unguided needle.
How we got here: QYResearch's $241.1 million 2030 figure for AV fistula needles specifically, rather than Fortune Business Insights' $96.89 billion figure for all vascular access procedures, is the more relevant ceiling because X9's device is sold alongside the needle itself, not as a replacement for catheters, ports or grafts.
X9 against how fistulas get cannulated today
| Method | Needle insertion | Status |
|---|---|---|
| X9 (power-assisted) | Guided, power-assisted | Breakthrough Device, Oct 2026 |
| Standard blind cannulation | By feel, unguided | Current practice, no device |
| X9 (imaging only) | Guided imaging, hand insertion | FDA cleared, K251673 |
| General point-of-care ultrasound | Assisted, hand insertion, off-label | Cleared for imaging, not fistula-specific |
From X9's own announcements, FDA records and published cannulation literature; not a clinical comparison.
What this designation does not resolve: X9 has not disclosed a filing timeline for the power-assisted system's own FDA clearance or marketing authorization, and ACCESS-2's 10-patient enrollment is a feasibility and safety signal, not the larger pivotal evidence a clearance submission would typically need. X9's total funding since its 2022 launch is reported inconsistently across trade sources — from $8.6 million in one Hartford Business Journal figure to $13.7 million in a CB Insights total — and this report has not reconciled the two.
- Designation: FDA Breakthrough Device Designation for the X9 Ultrasound System with Power-Assisted Needle Insertion, announced 26 October 2026.
- Clinical data: ACCESS-2, a 10-patient feasibility and safety study, reported successful needle placement, dialysis initiation and no serious device-related adverse events.
- Existing clearance: X9's ultrasound-only system already holds FDA 510(k) clearance (K251673) and is in use.
- Not yet public: a filing date for the power-assisted system's own clearance, and a single reconciled total-funding figure.
Sources & further reading
- X9, Inc., “X9 Receives FDA Breakthrough Device Designation for Investigational Dialysis Cannulation System and Completes Second Clinical Study,” GlobeNewswire, 26 October 2026. globenewswire.com
- FDA 510(k) Premarket Notification database, X9 Ultrasound System, K251673. accessdata.fda.gov
- MedTech Dive, coverage of X9's launch and DaVita backing. medtechdive.com
- Hartford Business Journal, “Wallingford startup X9 raises $8.6M to develop dialysis needle technology.” hartfordbusiness.com
- ClinicalTrials.gov, “Guided Needle Insertion for Vascular Access,” NCT07548151. clinicaltrials.gov
- Valuates Reports, Global Arteriovenous (AV) Fistula Needle market report (QYResearch). reports.valuates.com
- Fortune Business Insights, Vascular Access Procedures Market. fortunebusinessinsights.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What exactly did FDA grant X9?
FDA granted a Breakthrough Device Designation, announced 26 October 2026, to the X9 Ultrasound System with Power-Assisted Needle Insertion — imaging and guidance intended to help clinicians find validated vascular access sites and perform guided needle insertion during hemodialysis cannulation. A Breakthrough Device Designation speeds FDA's review process; it is not a clearance, and the power-assisted system remains investigational and is not for sale.
Is this X9's first FDA interaction?
No. X9 already holds FDA 510(k) clearance (K251673) for an ultrasound-only version of its system, classified by FDA as ultrasound imaging for vascular access for hemodialysis. The newly designated power-assisted version, which adds guided needle insertion to that imaging, is the one still working through FDA review.
What did the ACCESS-2 study show?
ACCESS-2, a single-center feasibility and safety study, enrolled 10 hemodialysis patients with arteriovenous fistulas. Per X9's announcement, it demonstrated successful needle placement and subsequent initiation of dialysis, met its primary safety objective, and reported no serious device-related adverse events. It followed an earlier first-in-human feasibility study announced in November 2025.
Who funds X9, and is it a public company?
X9 is privately held. It launched in 2022 from the ExploraMed incubator in Mountain View, California, with DaVita's venture arm as its primary seed investor; DaVita also led a later funding round. A Hartford Business Journal report put an earlier X9 raise at $8.6 million for continued development of its needle-insertion technology.
